Skip to evidence report

T.CD8_transitional.effector_primed: Studies

How association tiers are defined — cell–trait and gene–trait

SCREATE tier definitions supplied by the atlas curator. This methods note explains the prepared classifications; it does not recompute or change any report scores or tiers.

Cell–trait tiers

Cell–trait links
Identify cell types whose regulatory activity is associated with a trait’s genetic signal.
Required for Specific or Relevant
The ICE-CREAM score derived from the mean metacell Z score must be ≥ 5.39, with BOTH nominal and adjusted ICE-CREAM P values ≤ 0.05.
Specific (Tier 1)
Also meets all cell-set enrichment analysis (CSEA) criteria in at least one tested comparison: nominal P ≤ 0.05 AND adjusted P ≤ 0.05 AND normalized enrichment score (NES) ≥ 1, all in that comparison. This indicates that trait-associated activity is concentrated in this cell type relative to the tested background.
Relevant (Tier 2)
Meets the ICE-CREAM requirements but not the additional CSEA criteria. The cell type may share trait-associated activity with other cell types.
Interpretation and report values
CSEA is cell-set enrichment analysis, analogous to gene-set enrichment analysis but using sets of cells along a ranked list of ICE-CREAM scores. The eligibility score derived from the mean metacell Z score is not the displayed mean IC score. Do not infer a tier from the displayed mean, its descriptive Significance column, or a single CSEA summary value. Reports preserve prepared tiers; Other means an available association outside Specific/Relevant, and unavailable is not zero or proof of biological irrelevance.
Meta traits and individual traits
Use the prepared tier for the exact meta trait or individual trait. A meta trait’s Best child CSEA FDR is the lowest available child FDR, not a combined or meta-trait significance test. Its displayed mean child NES is descriptive, not a new CSEA test. These summaries must not be used to reconstruct or override the meta-trait tier.

Gene–trait priorities (variant–tCRE–gene evidence)

Variant–tCRE–gene links
Candidate variants connect to genes through overlapping promoters or distal transcribed cis-regulatory elements (tCREs) linked to gene promoters by the Activity-by-Contact (ABC) model.
Required genetic support
The variant belongs to a purity-passing SuSiE credible set OR qualifies for Borzoi rescue. Borzoi rescue requires BOTH a variant-causality score ≥ 0.3 AND linkage disequilibrium with the lead variant of r² ≥ 0.2.
Required cellular support
The overlapping promoter has positive tCRE activity OR the distal element has a passing cell-specific ABC link to the gene, in a Specific or Relevant cell subtype (L1S) or fine-grained state (L2). BOTH genetic and cellular support are required for High or Medium priority.
High priority
Among records meeting both minimum requirements, High requires a genetic score ≥ 0.5 AND a Layer 1 correlation > 0.3 between tCRE activity and the trait’s cellular profile across cell subtypes.
Medium priority
Meets both minimum requirements but not one or both additional High thresholds. The genetic score is the higher of the SuSiE posterior inclusion probability (PIP) and the Borzoi variant-causality score.
Same-record evidence and aggregation
Each priority requires genetic and cellular evidence supporting the SAME variant–tCRE–gene record. Do not combine thresholds or evidence from different records to create a qualifying link. A gene receives the highest priority observed among its supporting records. A tCRE summary uses supporting records for that exact tCRE, not every trait of its linked genes. Separately displayed aggregate scores do not relax the same-record rule.
Limits of interpretation
A priority is candidate-association evidence, not proof of a causal variant, causal gene, causal cell type or treatment efficacy. Missing evidence is unavailable, not zero. MAGMA −log10(P), displayed credibility scores, cellular-context scores and G/C tier codes must not be substituted for these eligibility tests; use the provided records and their documented fields.

State · 6,528 full-atlas cells · all tissues.

Marker genes and cell annotation · Open this population in Cell Browser →

ICE-CREAM (IC) is −log10(P) from a permutation test. An IC score of 3 corresponds to an unadjusted P value of 0.001; 5.5 is the multiple-testing-corrected significance threshold across all metacells. The Significance categories are Significant for IC > 5.5, Nominal for 3 ≤ IC ≤ 5.5, and Nonsignificant for IC < 3. These reports display mean IC scores across full-atlas populations, not the UMAP sample. The categories apply to the displayed scores: a cell-group mean or an average across individual traits is descriptive and is not itself a newly tested P value or a new multiple-testing correction. All scores are retained. Enrichment is not proof of causality or treatment efficacy.

Rows 1–1,000 of 12,313; ranked by score descending. Equal values use name/identifier order.

Studies ranked for T.CD8_transitional.effector_primed
#Trait / studyIndividual trait IDMean IC score
1Allergic contact dermatitisFING0000006859.18
2CXCL16 levelsGCST9046892855.04
3FCRL6 levelsGCST9046920954.06
4CXCL9 levelsGCST9046893552.24
5Psoriatic arthritisGCST9024395651.28
6Psoriasis vulgaris (PheCode 696.41)GCST9047619050.54
7GZMA/GZMH ratioGCST9031500849.46
8Nasal polypFING0000085848.78
9CD160/KLRB1 ratioGCST9031373148.67
10Multiple sclerosisGCST9047583348.58
11TNFRSF8 levelsGCST9047091548.46
12IL15 levelsGCST9046955647.60
13Psoriasis (PheCode 696.4)GCST9047618747.08
14Psoriasis and related disorder (PheCode 696)GCST9047618646.59
15GNLY/GZMA ratioGCST9031494945.37
16CRTAM/FCRL6 ratioGCST9031427445.31
17RPE levelsGCST9047049544.95
18GNLY levelsGCST9046937244.62
19TXNL1 levelsGCST9047099344.34
20Lymphocyte countGCST9002598444.29
21Type 1 diabetesGCST9000052944.27
22GZMH levelsGCST9046942544.22
23PAFAH1B3 levelsGCST9047014543.71
24Lymphoid neoplasms (B-cell phenocluster)GCST9062473643.66
25MS-disease / Multiple SclerosisFING0000083943.65
26CD244/CRTAM ratioGCST9031376343.64
27CD160/NCR1 ratioGCST9031373242.82
28CRTAM/VCAM1 ratioGCST9031428141.97
29Lymphocyte countGCST9001874241.25
30Second line medication for Crohn's diseaseFING0000128441.06
31CD160/CXCL16 ratioGCST9031372840.88
32Lymphoid neoplasms (somatic mutation group 2 phenocluster)GCST9062475040.41
33RBFOX3 levelsGCST9047043240.30
34IL18 levelsGCST9042841140.07
35Chronic sinusitisFING0000029840.01
36Prescriptions - tramadol | opioid analgesic,selective serotonin re-uptake inhibitor,norepinephrine re-uptake inhibitorUKBB0000070640.00
37Prescriptions - opioid analgesic|selective serotonin re-uptake inhibitor|norepinephrine re-uptake inhibitorUKBB0000069440.00
38CD48/CRTAM ratioGCST9031383939.87
39GZMA/LTA ratioGCST9031501239.59
40Left-hemisphere dorsal attention network to amygdala white-matter structural connectivityGCST9030270639.54
41PsoriasisGCST9001901639.44
42GZMA/GZMB ratioGCST9031500739.37
43Lymphocyte countGCST9000231739.31
44IFNG levelsGCST9046951539.20
45lymphocyte (absolute count, mean, inv-norm transformed)GCST9047542638.43
46Reimbursement for rheumatic diseasesFING0000124738.27
47Asthma-related infectionsFING0000011837.73
48LTA levelsGCST9046981337.40
49CCL17/PDGFB ratioGCST9031368837.31
50Type 1 diabetesGCST9001379137.26
51lymphocyte (absolute count, maximum, inv-norm transformed)GCST9047542337.00
52lymphocyte (absolute count, minimum, inv-norm transformed)GCST9047542936.99
53ITGAL levelsGCST9046963736.84
54Papulosquamous disordersFING0000114436.63
55NCR1 levelsGCST9047000936.29
56mean corpuscular hemoglobin (MCH, mean, inv-norm transformed)GCST9047544435.67
57Atopic dermatitisFING0000012535.53
58Dermatitis and eczemaFING0000040235.44
59HLAE/IL15 ratioGCST9031506135.35
60IDO1 levelsGCST9046950634.98
61SNRPB2 levelsGCST9047069734.93
62Pain type(s) experienced in last month - Pain all over the body | PainUKBB0000063234.89
63AsthmaGCST9046811234.77
64LAT/LYN ratioGCST9031528334.74
65Lymphoid neoplasms (drug group 1 phenocluster)GCST9062474034.66
66APRT levelsGCST9046834534.36
67Pulmonary fibrosisGCST9001868834.01
68IL2RB levelsGCST9046958633.91
69Lymphoid neoplasmsGCST9062474333.87
70Rheumatoid arthritisGCST9013222333.84
71Rheumatoid arthritisFING0000126733.79
72Asthma | respiratoryUKBB0000005433.41
73GZMH/KLRD1 ratioGCST9031501633.13
74BOLA2 or BOLA2B levelsGCST9046846032.92
75Autoimmune diseases excluding thyroid diseasesFING0000013232.72
76Asthma-related acute respiratory infectionsFING0000011732.63
77Thyroid peroxidase antibody positivity in pregnancyGCST9043520232.58
78Asthma | Chronic lower respiratory diseasesUKBB0000005332.50
79HSIL lesion of the cervix uteriFING0000062432.33
80EGFL7 levelsGCST9046908332.14
81Rash and other nonspecific skin eruption (PheCode 687.1)GCST9047616731.93
82CD8A levelsGCST9046865531.89
83Lymphocyte count | Blood countUKBB0000041131.79
84GZMA/TNFRSF8 ratioGCST9031501431.52
85Allergy/adverse effect of penicillin | injuries & poisoningsUKBB0000002831.47
86Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complicationsGCST9009311331.27
87eosinophil (absolute count, maximum, inv-norm transformed)GCST9047528831.11
88eosinophil (absolute count, mean, inv-norm transformed)GCST9047529131.09
89Lymphocyte count (UKB data field 30120)GCST9046808231.03
90Lymphocyte countGCST9000238831.03
91Personal history of allergy to drugs, medicaments and biologocal substances | Persons with potential health hazards related to family and personal history and certain conditions influencing health statusUKBB0000064130.88
92PsoriasisFING0000122230.79
93IL15/NCR1 ratioGCST9031515030.77
94Lymphocyte countGCST9000231630.70
95CD5/TNFRSF9 ratioGCST9031386230.67
96KIR3DL1 levelsGCST9046968730.60
97GZMB/IL15 ratioGCST9031501530.57
98Eosinophill count | Blood countUKBB0000020630.56
99ACYP1 levelsGCST9046821430.54
100Asthma (adult onset)GCST00779930.48
101PsoriasisGCST9046814730.46
102Eosinophil countGCST00460630.32
103Lymphocyte countGCST00462730.28
104CD160 levelsGCST9046859930.12
105Diseases of hair and hair follicles (PheCode 704)GCST9047620929.98
106eosinophil (absolute count, minimum, inv-norm transformed)GCST9047529429.98
107Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Asthma | Medical conditionsUKBB0000009829.92
108FCRL6/GZMA ratioGCST9031480629.39
109eosinophil (fraction, maximum, inv-norm transformed)GCST9047529729.15
110AsthmaGCST01004228.95
111Poisoning by antibiotics | injuries & poisoningsUKBB0000065328.90
112CD48/FCRL6 ratioGCST9031384028.87
113Neutrophil percentage of granulocytesGCST00462328.82
114Seropositive rheumatoid arthritis, wideFING0000129828.80
115Principal component-derived dietary pattern 26GCST9013303128.78
116KDM3A levelsGCST9046967128.77
117Sum eosinophil basophil countsGCST00462428.66
118CXCL10 levelsGCST9046892328.64
119Asthma/COPD (KELA code 203)FING0000012128.61
120Mouth/teeth dental problems - Mouth ulcers | MouthUKBB0000048828.59
121IL15/IL18BP ratioGCST9031514828.30
122Suggestive for eosinophilic asthmaFING0000134428.23
123First line medication for Crohn's diseaseFING0000054428.21
124Atopic dermatitisGCST9002716128.19
125eosinophil (fraction, minimum, inv-norm transformed)GCST9047530328.16
126Chronic lymphocytic leukemiaGCST9062473828.13
127GBP1 levelsGCST9046931128.10
128lymphocyte (fraction, maximum, inv-norm transformed)GCST9047543228.05
129Eosinophill percentage (UKB data field 30210)GCST9046806927.90
130GZMA/TNFRSF4 ratioGCST9031501327.85
131Eosinophil percentage of granulocytesGCST00461727.84
132S100A11/S100A12 ratioGCST9031579827.79
133Disorders of orbitFING0000044927.78
134Plasma ascorbic acid 2-sulfate levels in chronic kidney diseaseGCST9026483227.74
135ARHGAP30 levelsGCST9046835427.70
136Ulcerative rectosigmoiditisFING0000139427.64
137Chronic dermatitis due to solar radiation (PheCode 938.2)GCST9047628827.61
138TBCA levelsGCST9047081227.59
139Autoimmune diseasesFING0000013127.57
140Rheumatoid arthritisGCST9013222427.56
141IL2RA/NCR1 ratioGCST9031516127.55
142Seborrhoeic dermatitisFING0000128227.38
143KLRB1 levelsGCST9046970927.37
144Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - None of the above | Medical conditionsUKBB0000010127.35
145Graves disease, strict definitionFING0000059227.26
146Eosinophil percentage of white cellsGCST00460027.18
147Type1 diabetes, definitions combined, early onsetFING0000138427.16
148SarcoidosisGCST9050348327.11
149CD7 levelsGCST9046864927.08
150Avoided activities or situations because of previous stressful experience in past month | Traumatic eventsUKBB0000008326.95
151CRTAM levelsGCST9046887126.71
152Non-cancer illness code, self-reported - asthma | Medical conditionsUKBB0000050626.71
153Asthma (childhood onset)GCST00780026.69
154CD244/FCRL6 ratioGCST9031376526.65
155Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Hayfever, allergic rhinitis or eczema | Medical conditionsUKBB0000010026.60
156Blood cell traits latent factor 3 (white cell)GCST9055924526.56
157Respiratory disease (confirmatory factor analysis Factor 11)GCST9030934526.55
158VEGFB levelsGCST9047103526.52
159Eosinophill percentage | Blood countUKBB0000020726.51
160Lymphoid leukemia, chronic (PheCode 204.12)GCST9047561326.50
161Thyroid peroxidase antibody levels in pregnancyGCST9043520126.25
162Seropositive rheumatoid arthritis, strict definitionFING0000129726.23
163Systemic lupus erythematosusGCST9001186626.23
164Chronic lower respiratory diseasesFING0000029026.22
165Seronegative rheumatoid arthritisFING0000129626.21
166HyperthyroidismGCST9046813626.10
167SMNDC1 levelsGCST9047068125.94
168Lichen ruber planus, wide definition including periferal and oral lichen planusFING0000072225.91
169CRTAM/GZMA ratioGCST9031427525.90
170TALDO1 levelsGCST9047080225.86
171IPCEF1/SERPINE1 ratioGCST9031518425.84
172KIR2DL3 levelsGCST9046968525.76
173CRTAM/LY9 ratioGCST9031427825.73
174Asthma (only as main-diagnosis) (more control exclusions)FING0000011425.63
175AsthmaGCST9001432525.63
176DNAJC21 levelsGCST9046901625.57
177GZMB levelsGCST9046942425.55
178Non-cancer illness code, self-reported - hypothyroidism/myxoedema | Medical conditionsUKBB0000051825.41
179AKT1S1/FHIT ratioGCST9031322825.36
180lymphocyte (fraction, mean, inv-norm transformed)GCST9047543525.32
181CD8 on Effector Memory CD8+ T cellGCST9000205625.32
182FCRL6/KLRD1 ratioGCST9031480725.31
183mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed)GCST9047544825.30
184CD5 levelsGCST9046864125.23
185Lymphocyte percentage | Blood countUKBB0000041225.22
186Smoking status (weighted GWA)GCST9026730325.21
187DKK1/IPCEF1 ratioGCST9031447125.12
188Hypothyroidism NOS (PheCode 244.4)GCST9047565325.11
189Psoriasis vulgarisFING0000122425.02
190eosinophil (fraction, mean, inv-norm transformed)GCST9047530024.93
191Other demyelinating diseases of the central nervous systemFING0000099524.92
192Hypothyroidism, strict autoimmuneFING0000065624.91
193HypothyroidismGCST9020416724.90
194TNFRSF17 levelsGCST9047090824.85
195PPM1B levelsGCST9047029624.80
196EDAR/EGF ratioGCST9031457324.79
197DTI TBSS MD Superior corona radiata LGCST9038459724.73
198lymphocyte (fraction, minimum, inv-norm transformed)GCST9047543824.70
199HypothyroidismGCST9046813824.68
200Eosinophil countGCST9000229824.63
201HSIL lesion of the cervix uteri, vagina or vulvaFING0000062524.62
202INSR levelsGCST9046962324.57
203Disorders of the thyroid glandFING0000046324.54
204Cerebrospinal fluid methylmalonate (MMA) levelsGCST9031824324.54
205Other hypothyroidism | Disorders of thyroid glandUKBB0000061124.51
206Eosinophil percentage of white cellsGCST9000238224.48
207Eosinophil countGCST9000238124.34
208Eosinophill count (UKB data field 30150)GCST9046806824.30
209Hypothyroidism | endocrine/metabolicUKBB0000033524.24
210Treatment/medication code - levothyroxine sodium | MedicationsUKBB0000084924.06
211Malignant neoplasm of bronchus and lung, excluding all cancers (controls excluding all cancers)FING0000075623.99
212Childhood asthma (age<16) (more control exclusions)FING0000027023.97
213Juvenile rheumatoid arthirtisFING0000070623.82
214Hypothyroidism NOS | endocrine/metabolicUKBB0000033623.73
215Type 1 diabetesGCST9001402323.71
216Mosaic chromosomal alteration of the X chromosomeGCST9016528723.69
217Idiopathic pulmonary fibrosisFING0000065923.69
218Lymphocyte percentage of white cellsGCST9000238923.68
219Treatment or medication use - levothyroxine sodium (UKB data field 20003_1141191044)GCST9004253523.67
220PALM2 levelsGCST9047015223.56
221Lymphocyte percentage (UKB data field 30180)GCST9046808323.56
222Blood cell traits latent factor 9 (white cell)GCST9055925123.54
223Asthma with exacerbation (PheCode 495.2)GCST9047602523.50
224MZB1 levelsGCST9046998723.48
225PolyarthropathiesFING0000118023.47
226Thyroid peroxidase antibody positivity with euthyroid in pregnancyGCST9043520323.46
227NBN levelsGCST9047000223.39
228Hypothyroidism (PheCode 244)GCST9047564723.38
229IridocyclitisFING0000069623.22
230CRTAM/ICAM3 ratioGCST9031427623.20
231DTI autoptx L1 cst l tractGCST9038514723.15
232Basal cell carcinoma (MTAG)GCST9013741123.04
233DTI autoptx MD cgc l tractGCST9038522423.04
234DTI autoptx MD str r tractGCST9038524422.95
235Non-cancer illness code, self-reported - hayfever/allergic rhinitis | Medical conditionsUKBB0000051322.93
236SMPD3 levelsGCST9047068522.88
237DTI TBSS MD Posterior limb of internal capsule LGCST9038459122.83
238RILP levelsGCST9047047122.78
239Prescriptions - antispasmodicUKBB0000066622.76
240SKAP1 levelsGCST9047064522.67
241Prescriptions - levothyroxine | thyroid hormoneUKBB0000068722.67
242Prescriptions - thyroid hormone | hormoneUKBB0000070522.67
243Rheumatoid arthritis (PheCode 714.1)GCST9047623022.58
244Takes medication for Thyroid problems?GCST9047527722.55
245LAIR2 levelsGCST9046972922.51
2463-methyl-2-oxobutyrate levelsGCST9019967722.49
247CRTAM/TNFRSF9 ratioGCST9031428022.36
248Neutrophils and lymphocytes in blood (confirmatory factor analysis Factor 35)GCST9030936922.32
249DTI TBSS L3 Genu of corpus callosumGCST9038452622.26
250Wheeze or whistling in the chest in last year (UKB data field 2316)GCST9004361422.24
251Non-cancer illness code, self-reported - hiatus hernia | Medical conditionsUKBB0000051522.19
252Thyroid problemsGCST9047527622.03
253Inflammatory bowel disease, strict (require KELA)FING0000067522.00
254GLO1 levelsGCST9046935821.95
255DTI TBSS MD Genu of corpus callosumGCST9038457421.95
256Noninfective enteritis and colitisFING0000088121.94
257CRTAM/KLRD1 ratioGCST9031427721.93
258Type 1 diabetes, definitions combinedFING0000138021.78
259CD6 levelsGCST9046864421.75
260Fluid intelligence score decline (difference score)GCST9056586221.62
261Other diseases of upper respiratory tractFING0000101221.62
262Primary biliary cholangitis (PBC)FING0000121121.51
263IFI30 levelsGCST9046950921.39
264Acute upper respiratory infectionsFING0000003421.29
265FASLG levelsGCST9046919121.22
266APRT/CD63 ratioGCST9031333421.20
267TNFSF12 levelsGCST9027484621.12
268LHPP levelsGCST9046976820.96
269Allergic disease (asthma, hay fever or eczema)GCST00503820.89
270CLEC1B/DAB2 ratioGCST9031408620.89
271Treatment/medication code - ibuprofen | MedicationsUKBB0000084720.79
272T1 FreeSurfer aseg MaskVol-to-eTIVGCST9038419220.77
273Wheeze or whistling in the chest in last year | BreathingUKBB0000091220.72
274Nonspecific chest pain | circulatory systemUKBB0000052720.71
275BMP7 levelsGCST9008815720.69
276Medication use (drugs affecting bone structure and mineralization)GCST9001877320.68
277PCBD1 levelsGCST9047016620.62
278SELPLG levelsGCST9047056820.58
279Volume of right basal nucleusGCST9047501520.49
280Ceramide (d18:2/22:0) levelsGCST9002468220.45
281HypothyroidismGCST9031932020.25
282Diseases of white blood cells (PheCode 288)GCST9047581220.23
283Malignant neoplasm of lip, excluding all cancers (controls excluding all cancers)FING0000076420.18
284CWC15 levelsGCST9046892020.10
285COPD/asthma/ILD related infectionsFING0000035320.08
286LYN/SIRT2 ratioGCST9031534920.05
287Erythematosquamous dermatosis (PheCode 690)GCST9047617019.98
288Multiple myeloma or monoclonal gammopathy of undetermined significanceGCST9062474619.94
289Seborrheic dermatitis (PheCode 690.1)GCST9047617119.86
290CD79B/TNFRSF4 ratioGCST9031390319.82
291Asthma (more control exclusions)FING0000011319.82
292TNFRSF19 levelsGCST9008894719.80
293DNA methylation-estimated granulocyte proportionsGCST9001428719.79
294CXCL16/NOTCH1 ratioGCST9031433919.78
295Sporadic miscarriageGCST01188819.68
296CD300A levelsGCST9046861919.56
297IL5RA/TNFRSF13B ratioGCST9031516419.53
298Asthma and allergyFING0000011519.51
299WARS levelsGCST9047106619.45
300T1 FreeSurfer BA lh V2 exvivo thicknessGCST9038552919.43
301Rosacea (PheCode 695.3)GCST9047617819.43
302Allergic asthma (mode)FING0000006619.41
303GZMA levelsGCST9046942319.39
304PDCD1 levelsGCST9047018119.25
305ConjunctivitisFING0000034619.23
306Melanomas of skin (PheCode 172.11)GCST9047557819.21
307aseg lh volume HippocampusGCST9000262419.16
308CLC levelsGCST9046876219.16
309Neurofibromatosis, type 2FING0000086719.08
310Graves' disease (PheCode 242.1)GCST9047564419.06
311Nasal polyps | respiratoryUKBB0000049418.94
312APBB1IP/POLR2F ratioGCST9031330018.92
313IL5RA levelsGCST9046960018.88
314HayfeverGCST9046813118.81
315DTYMK levelsGCST9046904918.78
316Other specified disorders of external earFING0000110418.76
317GOPC/IRAK4 ratioGCST9031495418.76
318Skin color (cheek, ITA value)GCST9050278018.73
319Ulcerative colitisGCST9001871318.70
320PIKFYVE levelsGCST9047023518.67
321Inflammatory bowel diseaseGCST9043218218.66
322Other/unspecified rheumatoid arthritisFING0000112618.65
323IL15/KLRD1 ratioGCST9031514918.48
324PAXX levelsGCST9047016118.47
325Colitis, primary sclerosing, strict definitionFING0000031318.45
326Lymphocyte percentage of white cellsGCST00463218.45
327LTA4H levelsGCST9046981218.35
328ICD10 O60: Preterm labor and deliveryGCST9045424218.27
329Eosinophil countGCST9000229918.26
330Other and unspecified tonsillitisFING0000095418.20
331CD101 levelsGCST9046859618.20
332Volume of right central nucleusGCST9047491618.17
333HSPA1A levelsGCST9046948718.04
334Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive)GCST9013222718.03
335Coeliac diseaseFING0000031218.02
336C5 levelsGCST9046850017.99
337Regional enteritis (PheCode 555.1)GCST9047606617.95
338TP53I3 levelsGCST9047093717.94
339Blood cell traits latent factor 17 (white cell)GCST9055925917.93
340Rheumatoid arthritisGCST9001869017.90
341Percentage of fucosylated structures (with bisecting GlcNAc) in total neutral plasma glycans (GP80)GCST9066852417.88
342PTPRC levelsGCST9047038017.86
343Disorders of sclera, cornea, iris and ciliary bodyFING0000045817.84
344ICD10 N87: Dysplasia of cervix uteriGCST9045421817.80
345Inflammatory bowel disease and other gasteroenteritis and colitis (PheCode 555)GCST9047606517.78
346Other (seronegative) rheumatoid arthritis, wideFING0000091717.75
347aparc-a2009s rh thickness G-temporal-middleGCST9000371417.73
348CD27/NBL1 ratioGCST9031377417.73
349Other acute lower respiratory infectionsFING0000092117.72
350NAP1L4 levelsGCST9046999817.63
351Ever SmokerFING0000052217.61
352Primary biliary cholangitisGCST9006144017.55
353Incidence of bisecting GlcNAc in all fucosylated disialylated structures (GP57)GCST9066873517.47
354DTI TBSS L3 Superior corona radiata LGCST9038454917.42
355LCN2/PGLYRP1 ratioGCST9031530617.37
356SIT1 levelsGCST9047064417.32
357KIR2DL2 levelsGCST9046968417.29
358Mean corpuscular hemoglobin concentrationGCST9001874517.21
359Omega-3 fatty acids to Omega-6 fatty acids ratioGCST9050239617.19
360ThyrotoxicosisFING0000136017.04
361Methods of admission to hospital (recoded) - Elective admission: Planned | Summary AdministrationUKBB0000046217.03
362BLNK levelsGCST9046844817.02
363Alcohol-induced chronic pancreatitisFING0000005517.02
364THBS2 levelsGCST9047085416.95
365Nasal polyp | Other diseases of upper respiratory tractUKBB0000049316.95
366Handedness (chirality/laterality) - Left-handed | Early life factorsUKBB0000030216.93
367CD244 levelsGCST9046861116.89
368SH2D1A levelsGCST9047061716.89
369SRP14 levelsGCST9047074216.88
370Multiple myelomaGCST9062474716.88
371Benign leiomyoma with endometriosis (controls excluding all cancers)FING0000014516.86
372AHNAK levelsGCST9046826116.84
373Atopic/contact dermatitis due to other or unspecified (PheCode 939)GCST9047628916.83
374Thyrotoxicosis with diffuse goitreFING0000136116.77
375MAPRE3 levelsGCST9046985916.73
376Mean reticulocyte volumeGCST9002597516.71
377X-21285 levelsGCST9020057616.66
378Crohn disease (strict definition, require KELA, min 2 HDR)FING0000036616.66
379Omega-3 fatty acids to total fatty acids percentageGCST9050246016.65
380Internal derangement of knee (PheCode 835)GCST9047628216.63
381Eosinophil countGCST9001873316.63
382CRTAM/PDCD1 ratioGCST9031427916.61
383PM: initial answer - Orange circle| Prospective memoryUKBB0000065216.61
384Time spent watching television (TV) | Physical activityUKBB0000082116.58
385Lymphoid neoplasms (P-cell phenocluster)GCST9062473716.58
386T1 FreeSurfer DK rh supramarginal volumeGCST9038578716.50
387Hypothyroidism, drug reimbursementFING0000065516.43
388Percentage of fucosylated structures (with bisecting GlcNAc) in total neutral plasma glycans (GP80)GCST9066875816.40
389Lung cancerGCST9001865516.39
390CCL17/CD69 ratioGCST9031368416.37
391OSMR levelsGCST9047013216.33
392STIP1 levelsGCST9047076416.33
393LCN2/S100A12 ratioGCST9031530916.26
394Plasma taurocholenate sulfate* levels in chronic kidney diseaseGCST9026604016.24
395Percentage of fucosylation of monogalactosylated structures in total neutral plasma glycans (GP74)GCST9066851816.22
396Left-hemisphere control network to amygdala white-matter structural connectivityGCST9030275716.21
397DCTN1/TRIAP1 ratioGCST9031443416.12
398Preterm labour and deliveryFING0000120916.11
399Primary biliary cholangitisGCST00312916.08
400Basal cell carcinoma (PheCode 172.21)GCST9047558216.06
401CLIC5 levelsGCST9042174016.04
402Overweight, obesity and other hyperalimentation | endocrine/metabolicUKBB0000062216.02
403CD48/SLAMF7 ratioGCST9031384216.00
404GP6/HPCAL1 ratioGCST9031496315.99
405Operation code - tonsillectomy +/- adenoids | OperationsUKBB0000056715.97
406Methods of admission to hospital (recoded) - Elective admission: Booked | Summary AdministrationUKBB0000046115.97
407aparc-Desikan rh volume insulaGCST9000283415.86
408Eosinophil countGCST9002598715.85
409ICD10 N84: Polyp of female genital tractGCST9045421615.83
410HLA-A levelsGCST9046945715.81
411mean corpuscular volume (MCV, minimum, inv-norm transformed)GCST9047547415.79
412Autoimmune hyperthyroidismFING0000013415.75
413FOXO1/USP8 ratioGCST9031487915.71
414PFKM levelsGCST9061880215.71
415Ceramide (d18:2/22:0) levelsGCST9002405415.66
416IL16 levelsGCST9046955715.65
417Non-cancer illness code, self-reported - eczema/dermatitis | Medical conditionsUKBB0000050915.64
418mean corpuscular volume (MCV, mean, inv-norm transformed)GCST9047547015.64
419Educational attainmentGCST00259815.62
420LSP1 levelsGCST9046981115.60
421Coeliac diseaseGCST9046812015.58
422AHSP/HMBS ratioGCST9031321715.53
423CRTAP levelsGCST9046887215.51
424Mean corpuscular hemoglobin concentrationGCST9000232915.50
425SarcoidosisFING0000127515.47
426Volume of right paralaminar nucleusGCST9047505115.45
427Other non-epithelial cancer of skin | neoplasmsUKBB0000061515.45
428Mean reticulocyte volume | Blood countUKBB0000045115.44
429ST13 levelsGCST9047075115.42
430CCL19 levelsGCST9046857115.40
431Ulcerative colitisGCST00413315.34
432JCHAIN levelsGCST9046966115.31
433IGBP1 levelsGCST9046952115.28
434PBLD levelsGCST9047016315.27
435KLRF1 levelsGCST9046971215.25
436GRAP2/SRC ratioGCST9031498915.25
437ChalazionFING0000026715.25
438Hair colour (natural, before greying) - Black | Sun exposureUKBB0000029515.19
439CD5/IL16 ratioGCST9031386115.19
440S100A12 levelsGCST9047051315.19
441Sicca syndrome [Sjögren]FING0000130415.16
442PAG1 levelsGCST9047014715.15
443mean corpuscular volume (MCV, maximum, inv-norm transformed)GCST9047546615.15
444Graves' diseaseGCST9001862715.11
445Basophil countGCST9000229314.99
446red blood cell count (RBC, mean, inv-norm transformed)GCST9047634714.96
447CD40LG/TRAF2 ratioGCST9031382814.94
448LBR/POLR2F ratioGCST9031529714.93
449ZNF830 levelsGCST9047110214.91
450DNAJB2 levelsGCST9046901314.91
451FCRL5/LY96 ratioGCST9031480314.91
452CD300E/EFNA4 ratioGCST9031379714.90
453Volume of left central nucleusGCST9047488314.78
454IDP dMRI TBSS ICVF Medial lemniscus RGCST9000433514.74
455EDAR/F2R ratioGCST9031457714.70
456Mean sphered cell volume (UKB data field 30270)GCST9046808914.65
457F-caffeinated/sweet liking (derived food-liking factor)GCST9009472014.60
458Lumbar disc prolapseFING0000073514.60
459Other malignant neoplasms of skin | Melanoma and other malignant neoplasms of skinUKBB0000061314.57
460Psoriatic arthropathiesFING0000122514.57
461SH2B3/TBL1X ratioGCST9031584114.56
462Lung adenocarcinomaGCST00474414.50
463Principal component-derived dietary pattern 21GCST9013302614.49
464Diseases of vocal cords and larynx+other diseases of upper respiratory tract, no elsewhere classifiedFING0000043214.48
465MelanomaGCST9001180914.43
466FUT8/RSPO1 ratioGCST9031489114.41
467T1 FreeSurfer DKT rh supramarginal volumeGCST9038437714.41
468mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed)GCST9047545014.37
469HBEGF/PLXNA4 ratioGCST9031503614.37
470CXCL11/DKK1 ratioGCST9031433414.35
471Volume of left anterior amygdaloid areaGCST9047493714.33
472Nasal polyps (PheCode 471)GCST9047601914.33
473Pilonidal cystFING0000116714.32
474CD27/TGFBR2 ratioGCST9031377614.31
475mean corpuscular hemoglobin (MCH, maximum, inv-norm transformed)GCST9047544214.26
476AsthmaGCST9047525914.25
477DTI TBSS MD Superior longitudinal fasciculus LGCST9038461314.24
478Treatment speciality of consultant (recoded) - Trauma & orthopaedics | Summary AdministrationUKBB0000083714.18
479Bread type: Wholemeal/wholegrain vs white and brown (UKB data field 1448)GCST9013296814.18
480Acute pancreatitisFING0000002714.18
481TOR1AIP1 levelsGCST9047093514.17
482IL10 levelsGCST9046954614.17
483HippSubfield lh volume CA4-bodyGCST9000268314.17
484ROR1/THBD ratioGCST9031578614.16
485PARK7 levelsGCST9047015914.15
486Skin cancerGCST9047557514.11
487Asthma-related pneumoniaFING0000011914.11
488CD27/TNFRSF9 ratioGCST9031377814.11
489CD27/DLL1 ratioGCST9031377114.09
490MICB or MICA levelsGCST9046990514.09
491Urine N-acetylglutamate levels in chronic kidney diseaseGCST9026556914.08
492Myo-inositol levelsGCST9024352714.07
493UGDH levelsGCST9047100614.07
494ENO3 levelsGCST9046911114.06
495aparc-Desikan lh area fusiformGCST9000307914.06
496LBR levelsGCST9046974414.04
497IBD (strict) with PSCFING0000065714.01
498Hair colour (natural, before greying): Dark brown (UKB data field 1747_4)GCST9004183914.00
499DTI autoptx L1 cst r tractGCST9038514814.00
500Ever taken cannabis | Cannabis useUKBB0000022413.95
501MAP2K1 levelsGCST9046985113.91
502T1 FreeSurfer DK lh lingual thicknessGCST9038563413.90
503Basophil countGCST9001872613.90
504CLEC4D/CLEC6A ratioGCST9031410913.87
505Obesity | endocrine/metabolicUKBB0000054413.86
506Percentage of monosialylation of core-fucosylated monogalactosylated structures without bisecting GlcNAc (GP41)GCST9066848513.84
507DXO levelsGCST9046905513.82
508Viral haemorrhagic fevers, not elsewhere classified/unspecifiedFING0000143313.81
509CD27/NECTIN4 ratioGCST9031377513.80
510T1 FreeSurfer aseg Right-PallidumGCST9038416413.80
511MICB_MICA/TEK ratioGCST9031544613.77
512mean corpuscular hemoglobin (MCH, mean, inv-norm transformed)GCST9047544613.77
513Rheumatoid arthritisGCST00067913.76
514Melanomas of skin, dx or hx (PheCode 172.1)GCST9047557713.72
515IDP dMRI TBSS OD Posterior limb of internal capsule LGCST9000442113.72
516Hair colour (natural, before greying) - Dark brown | Sun exposureUKBB0000029713.70
517BCL2 levelsGCST9046843313.65
518Obesity | Obesity and other hyperalimentationUKBB0000054513.63
519Malignant neoplasm of skin, excluding all cancers (controls excluding all cancers)FING0000077213.61
520FCRL5/ICAM3 ratioGCST9031480213.61
521Belief that own life is meaningful | Happiness and subjective well-beingUKBB0000009013.59
522STX6 levelsGCST9047077413.58
523UBXN1 levelsGCST9047100413.56
524MAVS/MED18 ratioGCST9031538913.53
525Skin cancerGCST9047518913.50
526Mean sphered cell volume | Blood countUKBB0000045213.49
527TNFSF14 levelsGCST9047092213.49
528CSNK1D levelsGCST9046888813.47
529Congenital malformations of ovaries, fallopian tubes and broad ligamentsFING0000033713.46
530DTI TBSS MD External capsule LGCST9038460513.46
531KLF4 levelsGCST9046969413.44
532TIGIT levelsGCST9047086513.44
533Omega-3 fatty acids to total fatty acids percentageGCST9050244813.42
534aparc-a2009s rh thickness G-oc-temp-med-LingualGCST9000369813.40
535CLPS/PLA2G1B ratioGCST9031414013.38
536Tea difference likingGCST9009485513.35
537White blood cell countGCST9002598513.35
538Other non-epithelial cancer of skin (PheCode 172.2)GCST9047558013.34
539Number of attempts | Prospective memoryUKBB0000053113.31
540Hair colour (natural, before greying): Red (UKB data field 1747_2)GCST9004183713.25
541PollinosisGCST9001868313.24
542PDCD5 levelsGCST9047018213.21
543Ulcerative colitis (strict definition, require KELA, min 2 HDR)FING0000138813.20
544Treatment/medication code - ventolin 100micrograms inhaler | MedicationsUKBB0000086013.17
545Monoclonal gammopathy of undetermined significanceGCST9062474513.17
546Paraproteinemia (PheCode 270.32)GCST9047571013.11
547LAT/PLXNA4 ratioGCST9031528613.09
548T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 101)GCST9032092013.09
549Principal component-derived dietary pattern 12GCST9013301713.06
550HippSubfield lh volume GC-ML-DG-headGCST9000267913.03
551Types of physical activity in last 4 weeks - None of the above | Physical activityUKBB0000087213.01
552neutrophil (fraction, minimum, inv-norm transformed)GCST9047554113.00
553Interpolated Year when non-cancer illness first diagnosed | Medical conditionsUKBB0000037112.99
554UCMA levelsGCST9024328512.90
555CDKN2D/FOXO1 ratioGCST9031398512.87
556FOXO3 levelsGCST9046926612.82
557Pre-existing hypertension complicating pregnancy, childbirth and the puerperiumFING0000120312.82
558ADAM15 levelsGCST9046821712.80
559T1 FreeSurfer a2009s lh S postcentral areaGCST9038473412.79
560DGKA levelsGCST9046898912.78
561Squamous cell carcinoma (PheCode 172.22)GCST9047558312.75
562DTI autoptx L3 str r tractGCST9038521712.75
563Pain in throat and chest | Symptoms and signs involving the circulatory and respiratory systemsUKBB0000062512.71
564CEP85 levelsGCST9046871612.66
565DNA methylation PhenoAge accelerationGCST9001429212.64
566CD27 levelsGCST9046861512.64
567neutrophil (fraction, mean, inv-norm transformed)GCST9047553812.63
568Celiac disease (PheCode 557.1)GCST9004415812.58
569Non-albumin protein levelsUKBB0000050312.54
570Crohn's disease NASFING0000036712.53
571CXCL16 levelsGCST9024052412.53
572DTI TBSS MD Anterior corona radiata LGCST9038459512.50
573KLRD1/LY9 ratioGCST9031526112.46
574Epstein-Barr virus ZEBRA antibody levelsGCST9000690112.46
575PM: initial answer - Blue square | Prospective memoryUKBB0000065112.46
576Plasma homoarginine levels in chronic kidney diseaseGCST9026534512.43
577Other dyspnea (PheCode 512.9)GCST9047604212.41
578Human herpes virus 7 U14 antibody levelsGCST9000690912.41
579PDCD1/TNFRSF8 ratioGCST9031561012.41
580BAG6/BMP6 ratioGCST9031345012.40
581HyperthyroidismGCST9031931912.40
582Bipolar disorderGCST00372412.39
583F2R/TNFRSF14 ratioGCST9031473912.37
584MVK/SERPINE1 ratioGCST9031550512.36
585PEAR1/PECAM1 ratioGCST9031564112.35
586Acute renal failureFING0000003012.28
587Mean corpuscular hemoglobinGCST9000239012.28
588Allergic conjunctivitisFING0000006712.26
589IDP T1 FAST ROIs R front operc cortexGCST9000253212.24
590Completion of the aide-memoireGCST9001279312.24
591CDKN2D/TACC3 ratioGCST9031399212.22
592Bread type - Wholemeal or wholegrain | DietUKBB0000010712.21
593DTI autoptx L3 slf r tractGCST9038521512.21
594FCRL5 levelsGCST9046920812.18
595TNF levelsGCST9047092412.18
596Psoriasis (vulgaris), strict definitionFING0000122312.16
597Basophil countGCST9002599712.14
598Crohn's diseaseGCST9044679312.13
599NRSN1 levelsGCST9024206212.09
600Neutrophill percentage (UKB data field 30200)GCST9046809312.08
601Neutrophil percentage of white cellsGCST9000239912.06
602Pain in limbFING0000113812.05
603SPINK2 levelsGCST9047072212.04
604Cervical cancerGCST9001181612.03
6055-oxoproline levelsGCST9024343712.01
606Biological Mother: High blood pressureGCST9047549012.00
607SEMA4D levelsGCST9047057311.96
608PLXNA4/SUSD1 ratioGCST9031568911.93
609HSPB1 levelsGCST9017931711.93
610GMPR2 levelsGCST9046936711.93
611CD27/CD79B ratioGCST9031377011.92
612Hernia abdominopelvic cavityGCST9008608711.90
613Prospective memory result | Prospective memoryUKBB0000071311.89
614ICD10 N97.8: Female infertility of other originGCST9045422511.88
615Biological Sibling: AsthmaGCST9047637211.86
616Lung cancerGCST00474811.85
617Ratio of bis-allylic bonds to double bonds in lipidsGCST9013274411.85
618DTI TBSS L2 Genu of corpus callosumGCST9038447811.83
619Fluid intelligence score decline (log-difference score)GCST9056585211.82
620DEFA1_DEFA1B/PTGDS ratioGCST9031445511.82
621KLRK1 levelsGCST9046971311.81
622ARHGAP25/RNF41 ratioGCST9031334511.76
623EDAR/ERBIN ratioGCST9031457511.75
624Mean reticulocyte volume (UKB data field 30260)GCST9046808811.74
625BCL2L15 levelsGCST9046843111.74
626Neutrophill percentage | Blood countUKBB0000049811.72
627BTN3A2 levelsGCST9046848111.72
628Bread type: Wholemeal or wholegrain (UKB data field 1448_3)GCST9013296611.71
629MSRA/PRDX5 ratioGCST9031549711.68
630AXIN1/MAVS ratioGCST9031341411.66
631Mean spheric corpuscular volumeGCST9000239711.65
632Other intervertebral disc disordersFING0000106311.65
633Oxalate (ethanedioate) levelsGCST9019967211.65
634TPSAB1 levelsGCST9047095111.64
635GGACT levelsGCST9046933311.63
636GP1BA/HBEGF ratioGCST9031495611.63
637BCR/FOXO1 ratioGCST9031349011.58
638Systemic connective tissue disordersFING0000135011.55
639Rheumatoid arthritis | musculoskeletalUKBB0000075711.55
640CD72 levelsGCST9046864611.54
641DTI TBSS MD Superior corona radiata RGCST9038459611.54
642DTI TBSS L3 Sagittal stratum LGCST9038455511.53
643Back pain (PheCode 760)GCST9047626611.52
644HBEGF/WWP2 ratioGCST9031503811.50
645DTI autoptx L1 slf r tractGCST9038516111.50
646HippSubfield lh volume GC-ML-DG-bodyGCST9000268111.49
647Eosinophil count varianceGCST9056568911.49
648XCL1 levelsGCST9047108111.48
649Mean reticulocyte volumeGCST9000239611.48
650Crohn's disease of small intestineFING0000036911.44
651Blood cell traits latent factor 12 (red cell)GCST9055925411.42
652Other dorsopathies, not elsewhere classifiedFING0000104111.42
653EDAR/TACC3 ratioGCST9031458911.42
654MAN2B2 levelsGCST9046984411.42
655Mean corpuscular hemoglobinGCST00463011.42
656Seminoma of testis, excluding all cancers (controls excluding all cancers)FING0000128911.39
657Mean corpuscular volumeGCST9000239211.39
658ALB/Globulin ratioUKBB0000002011.38
659Rheumatoid arthritis and other inflammatory polyarthropathies | musculoskeletalUKBB0000075811.36
660MAVS/TBL1X ratioGCST9031539911.35
661Type 1 diabetesGCST9001870511.35
662QDPR levelsGCST9047040011.32
663HippSubfield lh volume Whole-hippocampusGCST9000268911.31
664IPCEF1/SPARC ratioGCST9031518611.31
665N2-acetyl,N6,N6-dimethyllysine levelsGCST9020069711.31
666Endometrial cancerGCST00646411.30
667LAYN/PTPRN2 ratioGCST9031529011.28
668ENO2/RWDD1 ratioGCST9031466711.28
669CEACAM8/PGLYRP1 ratioGCST9031400311.28
670HippSubfield lh volume Hippocampal-tailGCST9000266811.21
671GPI levelsGCST9046939111.18
672CCS levelsGCST9046859411.16
673APRT/PSME1 ratioGCST9031333811.13
674Mean corpuscular volume (UKB data field 30040)GCST9046808611.13
675DTI TBSS MD Superior longitudinal fasciculus RGCST9038461211.13
676Mouth/teeth dental problems - None of the above | MouthUKBB0000048911.12
677Actinic keratosisFING0000001311.11
678Eosinophil percentage of white cells varianceGCST9056569011.10
679KYNU/SCLY ratioGCST9031526511.07
680Cervical disc disordersFING0000026511.06
681FUT8/TNFSF14 ratioGCST9031489511.04
682Mean corpuscular haemoglobin (UKB data field 30050)GCST9046808411.04
683Ulcerative colitis (PheCode 555.2)GCST9004415511.03
684DNAJC9 levelsGCST9046901811.03
685CDH17/PTPRM ratioGCST9031394311.02
686ITGB2 levelsGCST9046964410.99
687CA3/HMBS ratioGCST9031358410.97
688Cancer of bronchus; lung (PheCode 165.1)GCST9047557310.96
689Overweight, obesity and other hyperalimentation (PheCode 278)GCST9047575910.94
690Attendance/disability/mobility allowance - None of the above | Other sociodemographic factorsUKBB0000005910.94
691TRAF2/WWP2 ratioGCST9031594310.94
692YOD1 levelsGCST9047109010.94
693CD20 on IgD- CD27- B cellGCST9000175410.93
694Age hay fever, rhinitis or eczema diagnosed | Medical conditionsUKBB0000001510.93
695Destinations on discharge from hospital (recoded) - Usual Place of residence | Summary AdministrationUKBB0000016710.91
696Actinic keratosis (PheCode 702.1)GCST9047620410.90
697PRL levelsGCST9047033210.90
698GBP4 levelsGCST9046931310.89
699DNAJA2/PLXNA4 ratioGCST9031450410.88
700SUMF1 levelsGCST9047078310.86
701Mean corpuscular haemoglobin | Blood countUKBB0000044710.84
702Neoplasm of uncertain behavior (PheCode 199)GCST9047560610.84
703RIDA levelsGCST9047046910.81
704CD163/ICAM1 ratioGCST9031373510.80
705APRT/MIF ratioGCST9031333610.77
706Principal component-derived dietary pattern 9GCST9013301410.76
707Sources of admission to hospital (recoded) - Usual Place of residence | Summary AdministrationUKBB0000078610.75
708Solitary pulmonary nodule (PheCode 514.2)GCST9047604410.74
709Acute sinusitisFING0000003110.74
710DTI TBSS MD Anterior limb of internal capsule LGCST9038458910.72
711Neoplasm of uncertain behavior of skin (PheCode 173)GCST9047558510.71
712Peripheral enthesopathies and allied syndromes | musculoskeletalUKBB0000064010.69
713Phenylacetate levelsGCST9019963010.68
714Crohn's diseaseGCST00413210.66
715CRACR2A/IRAG2 ratioGCST9031422710.64
716CRYBB1 levelsGCST9046887410.64
717Cancer within the respiratory system (PheCode 165)GCST9047557110.61
718Early-onset myasthenia gravisGCST9009346510.61
719CD58/MEGF10 ratioGCST9031385310.60
720PTPRS levelsGCST9047038710.60
721Acute bronchitisFING0000002110.57
722Spondylopathies (FG)FING0000132610.56
723neutrophil (fraction, maximum, inv-norm transformed)GCST9047553510.54
724Ulcerative colitis, NASFING0000139010.53
725Symptoms involving digestive system (PheCode 561)GCST9047606910.49
726ITGB1BP2/TIA1 ratioGCST9031522210.47
727CC2D1A/STAMBP ratioGCST9031366410.47
728SOD1 levelsGCST9047070410.46
729SH3GLB2 levelsGCST9047062110.46
730HNRNPUL1 levelsGCST9046947010.44
731Volume of right accessory basal nucleusGCST9047500910.44
732Telomere length (principal component 1)GCST9043514410.42
733DTI TBSS MD Cingulum cingulate gyrus LGCST9038460710.42
734CCL3 levelsGCST9046858210.41
735VSTM2B levelsGCST9047105610.37
736AK1 levelsGCST9046826910.37
737IL7 levelsGCST9046960610.34
738HippSubfield lh volume CA4-headGCST9000268210.34
739Parental longevity (combined parental age at death)GCST00670210.32
740PTRHD1 levelsGCST9047038910.31
741VNN2 levelsGCST9047104410.31
742CASP10 levelsGCST9046854210.29
743CD84/F2R ratioGCST9031391210.29
744EDIL3 levelsGCST9046907210.28
745FCRL2/LY9 ratioGCST9031479910.26
746IGF1R levelsGCST9046952410.26
747Degenerative skin conditions and other dermatoses (PheCode 702)GCST9047620210.24
748Rheumatoid arthritis and other inflammatory (PheCode 714)GCST9047622810.23
749Dermatomycosis (PheCode 110.2)GCST9047556510.21
750SIAE levelsGCST9047062910.20
751Lichen simplex chronicus and prurigoFING0000072510.20
752ITGB7 levelsGCST9046964710.19
753Basal cell carcinoma, including avohilmo, excluding all cancers (controls excluding all cancers)FING0000014310.17
754Other systemic involvement of connective tissue (FG)FING0000111610.14
755Mean corpuscular volumeGCST00460210.13
756VCAM1 levelsGCST9047103110.13
757aparc-DKTatlas lh area fusiformGCST9000323910.13
758SNX15 levelsGCST9047069910.13
759Tea with sugar likingGCST9009485710.11
760PRG3 levelsGCST9047032310.11
761Current SmokerFING0000037110.07
762Ankylosing spondylitisFING0000008910.06
763BOC levelsGCST9046845810.06
764IMPACT levelsGCST9046961110.04
765TNF/TNFRSF1B ratioGCST9031594210.03
766CD6/EZR ratioGCST9031389010.01
767PEBP1 levelsGCST904702059.99
768Ingrowing nail (PheCode 703.1)GCST904762089.97
769Gastric ulcerGCST900186319.94
770CXCL5/PLXNA4 ratioGCST903143519.90
771GRAP2/MAP4K5 ratioGCST903149829.90
772Mean corpuscular volume | Blood countUKBB000004499.90
773ATOX1/SNAP29 ratioGCST903133749.88
774SNAP29/VEGFC ratioGCST903158629.88
775APRT/EREG ratioGCST903133359.84
776ELOA/POLR2F ratioGCST903146439.84
777DorsalgiaFING000004729.83
778NELL2/SEZ6L ratioGCST903155369.82
779Peripheral or central vertigo (PheCode 386.2)GCST904759079.81
780PXN levelsGCST904703969.81
781COX5B/GFER ratioGCST903142009.80
782Ulcerative colitisGCST904467959.80
783FCER2/TNFRSF9 ratioGCST903147919.80
784T1 FreeSurfer a2009s lh S central thicknessGCST903847869.80
785Sjögren's syndromeGCST900187009.79
786Phosphatidylcholine acyl-alkyl C36:4 levelsGCST902400729.77
787FHIT/GLOD4 ratioGCST903148179.76
788SERPINE1/USP8 ratioGCST903158359.74
789CD48 levelsGCST904686359.73
790FOXO1/NUB1 ratioGCST903148749.73
791IL32 levelsGCST904695919.73
792FKBP4 levelsGCST904692439.73
793LBR/LGALS8 ratioGCST903152949.72
794SLAMF8 levelsGCST904706529.71
795Takes medication for Skin condition (ex. Eczema, Psoriasis)?GCST904752759.70
796Skin cancer | neoplasmsUKBB000007729.68
797Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T484ECGA0004849.68
798Never eat wheat vs no wheat restrictions (UKB data field 6144)GCST901329329.67
799DLG4 levelsGCST904690019.66
800CDA levelsGCST904686609.66
801Basal cell carcinoma, excluding all cancers (controls excluding all cancers)FING000001429.66
802DBNL/EDAR ratioGCST903144169.65
803T1 FreeSurfer BA lh BA2 exvivo volumeGCST903855349.65
804UrticariaFING000014089.63
805CXCL16 levelsGCST900120599.63
806Pain in jointFING000011379.63
807Carboplatin drug response (IC50)GCST900117839.63
808Rhodanobacter abundance in stoolGCST900325369.62
809Trouble falling asleep when you first go to bedGCST904763859.62
810Lower back pain or/and sciaticaFING000007319.60
811EDAR/LAT2 ratioGCST903145829.60
812CCR2 on CD14+ CD16- monocyteGCST900020049.60
813RCC1 levelsGCST904704439.60
814DTI autoptx L2 slf l tractGCST903851879.59
815Strenuous sports or other exercisesGCST0061009.56
816PDGFB/TNFSF13 ratioGCST903156329.55
817ICAM3/SLAMF7 ratioGCST903151239.53
818Poultry consumptionGCST901329969.53
819CA1/HMBS ratioGCST903135739.52
820EczemaGCST904681269.48
821TOP2B levelsGCST904709349.47
822Fibroblastic disordersFING000005429.39
823DTI TBSS MD Body of corpus callosumGCST903845759.39
824Severity of induration at injection site at the injection site after COVID-19 booster vaccinationGCST904544099.39
825BCR/DECR1 ratioGCST903134899.38
826aseg lh volume Accumbens-areaGCST900026269.37
827APP/BIN2 ratioGCST903133169.36
828AsthmaGCST904760249.36
829DTI TBSS L2 External capsule LGCST903845099.36
830GRHPR levelsGCST904694009.35
831Late-onset myasthenia gravisGCST900934669.35
832Percentage of fucosylation of monogalactosylated structures (with bisecting GlcNAc) in total neutral plasma glycans (GP82)GCST906685269.35
833EPHB6/TNFRSF9 ratioGCST903146829.30
834IGLC2 levelsGCST904695369.28
835Neutrophil percentage of white cellsGCST0046339.27
836APP/PPP1R12A ratioGCST903133309.26
837Blood cell traits latent factor 20 (red cell)GCST905592629.26
838Prurigo nodularisFING000012209.25
839Tryptophan betaine levelsGCST901998199.24
840Other malignant neoplasms of skin (=non-melanoma skin cancer), excluding all cancers (controls excluding all cancers)FING000010679.23
841PSAPL1 levelsGCST902423549.22
842Dissociative [conversion] disordersFING000004689.21
843HMBS/PKLR ratioGCST903150639.19
844Shortness of breath (PheCode 512.7)GCST904760409.18
845F11R/PLXNA4 ratioGCST903147249.17
846TRAF3 levelsGCST904709579.16
847Chromatiales abundance in stoolGCST900323189.15
848CCL13/CCL17 ratioGCST903136749.14
849CAPG levelsGCST904685379.13
850DTI TBSS L3 Posterior thalamic radiation LGCST903845539.13
851Fibrosis and cirrhosis of liverFING000005439.12
852TNFRSF9 levelsGCST904709169.12
853Primary sclerosing cholangitisGCST0040309.10
854F2R/SNX9 ratioGCST903147369.09
855FCRL1/TCL1A ratioGCST903147959.09
856MZB1/TNFRSF13B ratioGCST903155099.09
857Excessive scarringGCST904833689.07
858Chronic hepatitis B infectionGCST900185849.07
859CA5A/GSTA1 ratioGCST903135919.07
860DTI TBSS MD Posterior corona radiata LGCST903845999.06
861IL22 levelsGCST904695829.05
862Basal cell carcinomaGCST900134109.04
863X-16087 levelsGCST902005379.03
864DorsopathiesFING000004739.02
865White blood cell countGCST900024078.99
866DTI TBSS L2 Posterior thalamic radiation RGCST903845048.99
867Dried fruit consumptionGCST901329808.97
868CASP8/PPP3R1 ratioGCST903136548.97
869All dysplastic lesions of the cervix uteriFING000000608.97
870HTRA2/SIAE ratioGCST903150978.95
871Physical activity (Total log acceleration 8am-10am)GCST900614138.95
872IL18BP/ROR1 ratioGCST903151558.93
873LY96 levelsGCST904698238.92
874OCLN levelsGCST904701148.92
875N-acetylmethionine levelsGCST902002898.89
876Volume of right whole amygdalaGCST904750578.89
877CD69/EDAR ratioGCST903138758.88
878Bifidobacterium catenulatum abundance in stoolGCST900322248.88
879Pollen allergyFING000011768.85
880Hair colour (natural, before greying): Black (UKB data field 1747_5)GCST900418408.83
881CD274 levelsGCST902748328.83
882BLMH/SERPINE1 ratioGCST903135208.82
883Symptoms concerning nutrition, metabolism, and development (PheCode 1002)GCST904755568.81
884Types of physical activity in last 4 weeks - Walking for pleasure (not as a means of transport) | Physical activityUKBB000008758.81
885CD40LG/TNFSF14 ratioGCST903138278.80
886DKK1/LGALS8 ratioGCST903144728.80
887DTI TBSS L1 Cingulum cingulate gyrus LGCST903844638.80
888Frequency of stair climbing in last 4 weeks | Physical activityUKBB000002668.79
889SNAP23/SNAP29 ratioGCST903158558.78
890Mean arterial pressure, manual reading | Cardiovascular measurementUKBB000004418.76
891HEXIM1/TRIAP1 ratioGCST903150548.75
892Crohn's disease of large intestineFING000003688.74
893APRT/NSFL1C ratioGCST903133378.74
894Crohns diseaseGCST904681218.74
895CA5A/GRPEL1 ratioGCST903135908.71
896CASP10/ING1 ratioGCST903136258.71
897Volume of right central nucleusGCST904750278.71
898Left-hemisphere visual network to accumbens white-matter structural connectivityGCST903026688.70
899HippSubfield lh volume Whole-hippocampal-headGCST900026888.70
900DTI TBSS L3 Superior longitudinal fasciculus RGCST903845648.69
901NT5C levelsGCST904700928.69
902TNFRSF14/TNFSF14 ratioGCST903159368.68
903Intended management of patient (recoded) - No overnight hospital stay | Summary AdministrationUKBB000003668.68
904TYRO3 levelsGCST904709978.66
905White blood cell countGCST900023748.66
906Diseases of the digestive systemFING000004298.66
907CD46/TIMP1 ratioGCST903138378.64
908MIF levelsGCST904699068.63
909PPP1R12A/VEGFC ratioGCST903157158.62
910Prescriptions - antipyreticUKBB000006658.61
911Prescriptions - paracetamol | antipyreticUKBB000006968.61
912Extrapyramidal and movement disordersFING000005278.60
913EndometriosisGCST900186198.59
914CXCL11 levelsGCST904689248.57
915Vanillactate levelsGCST901999788.56
916DTI autoptx L3 ifo l tractGCST903852058.55
917DTI TBSS MD Anterior corona radiata RGCST903845948.53
918CLEC1B levelsGCST904687688.51
919FKBP1B/PRDX5 ratioGCST903148338.50
920Suppurative and unspecified otitis mediaFING000013468.48
921Osteoarthrosis NOS (PheCode 740.9)GCST904762568.45
922Never eat wheat vs no eggs, dairy, wheat or sugar restrictions (UKB data field 6144)GCST901329318.44
923TNFRSF13B/TNFRSF9 ratioGCST903159328.43
924ThalamNuclei rh volume MGNGCST900027378.43
925Parkinson's diseaseFING000011508.42
926DTI autoptx MD atr l tractGCST903852228.41
927DAB2/FKBP1B ratioGCST903143628.41
928SDC4/SEMA4D ratioGCST903158188.40
929MAD1L1/POLR2F ratioGCST903153548.40
930Edema (PheCode 782.3)GCST904762728.40
931ENO2 levelsGCST904691108.39
932EIF4G1/FOXO1 ratioGCST903146348.39
933TXNDC15 levelsGCST904709908.38
934Polyp of the female genital tractFING000011908.38
935IDP dMRI TBSS FA Posterior limb of internal capsule RGCST900038958.38
936NMT1 levelsGCST904700598.37
937PDCD1/TNFRSF4 ratioGCST903156098.34
938AIDA levelsGCST904682658.31
939AsthmaGCST0068628.31
940CCL5/LAMA4 ratioGCST903137038.30
941CASP3/LYN ratioGCST903136358.30
942CCL22/PDGFB ratioGCST903136928.28
943RAP1A levelsGCST904704258.28
944Multiple myeloma, Monoclonal gammopathy of undetermined significance (MGUS), excluding all cancers (controls excluding all cancers)FING000008468.27
945Other symptoms of respiratory system (PheCode 512)GCST904760398.27
946FOXO1/MAP4K5 ratioGCST903148728.25
947FHIT levelsGCST904692388.25
948F2R levelsGCST904691688.24
949CDC37/SNAP29 ratioGCST903139358.21
950DTI autoptx MD slf r tractGCST903852428.20
951CD74/NPDC1 ratioGCST903138958.19
952Omega-3 fatty acid levelsGCST905024228.17
953EDAR/SNAP23 ratioGCST903145878.16
954HBEGF levelsGCST904694338.15
955PLXNA4/SRPK2 ratioGCST903156888.14
956ZNRD2 levelsGCST904711038.13
957CXCL9 levelsGCST902747848.12
958TNFSF13B levelsGCST904709208.12
959Dried fruit likingGCST900947568.11
960CDC27 levelsGCST904686648.06
961CCN2/ENO2 ratioGCST903137128.05
962CCL5/SELP ratioGCST903137058.04
963N-acetyl-1-methylhistidine levelsGCST902006908.04
964Aplastic anemia (PheCode 284)GCST904757838.03
965Mineral and other dietary supplements - Zinc | MedicationUKBB000004768.03
966ADD1 levelsGCST904682338.02
967SLITRK2 levelsGCST904706708.02
968Never eat sugar vs no sugar restrictions (UKB data field 6144)GCST901329348.01
969RNASE3 levelsGCST904704778.01
970Methionine sulfone levelsGCST901999618.00
971TP53BP1 levelsGCST904709368.00
972PRG2 levelsGCST904703228.00
973PADI4 levelsGCST904701437.99
974PLAUR levelsGCST900120517.98
975ADH4/CA5A ratioGCST903131897.97
976Hepatic cancerGCST900186387.97
977Left-hemisphere dorsal attention network to putamen white-matter structural connectivityGCST903027037.97
978KLRB1/KLRD1 ratioGCST903152607.97
979APEX1 levelsGCST904683297.96
980ICD10 O13: Gestational hypertensionGCST904542327.96
981Scar conditions and fibrosis of skin (PheCode 701.2)GCST904761987.95
982PDGFB levelsGCST904701897.94
983DAPP1/ITGB1BP2 ratioGCST903143887.93
984DermatitisFING000004017.92
985Blood cell traits latent factor 22 (white cell)GCST905592647.92
986CCL5/TACC3 ratioGCST903137077.92
987TIMP3 levelsGCST904708717.90
988Viral warts & HPV (PheCode 78)GCST904755557.90
989Principal component-derived dietary pattern 42GCST901330477.88
990IDP dMRI TBSS L1 Posterior limb of internal capsule RGCST900040937.86
991UROD levelsGCST904710167.86
992LAMA4/PDGFB ratioGCST903152737.86
993CLEC1B/HBEGF ratioGCST903140927.85
994TTN levelsGCST904709847.84
995DTI TBSS MD Cingulum cingulate gyrus RGCST903846067.84
996IDP dMRI TBSS L3 Posterior limb of internal capsule RGCST900041897.83
997IDP T1 FAST ROIs V cerebellum VIIIbGCST900025827.82
998FUT8 levelsGCST904692817.81
999TSC1 levelsGCST904709727.81
1000FYN levelsGCST902432007.80